OBJECTIVE: Genetic risk factors for essential hypertension are largely unknown. The aim of the present study was to assess the association of 77 previously characterized gene variants in 52 candidate genes from various biological pathways with blood pressure (BP) progression and incident hypertension. METHODS: We analyzed data from 18 738 white women who participated in a prospective cohort study and were free of hypertension at baseline. BP progression at 48 months and incident hypertension during the entire follow-up according to the different genotypes were assessed by logistic regression and Cox proportional-hazards models, respectively. RESULTS: At 48 months of follow-up, 7889 of 16 635 women (47.4%) had BP progression. Only three of 70 polymorphisms with a minor allele frequency of at least 2% had a significant association with BP progression. The odds ratio [95% confidence interval (CI)] for 5,10-methylenetetrahydrofolate reductase (MTHFR) rs1801133 (minor allele T), natriuretic peptide precursor A (NPPA) rs5063 (minor allele A) and NPPA rs5065 (minor allele C) were 1.05 (1.00-1.10), 0.84 (0.76-0.94) and 0.93 (0.88-1.00), respectively. After adjustment for multiple testing using the false discovery rate, only the NPPA rs5063 association remained significant. During a median follow-up of 9.8 years, 5540 of 18 738 women developed incident hypertension. Only five of 70 polymorphisms were significantly associated with incident hypertension. The hazard ratio (95% CI) for interleukin 6 (IL-6) rs1800795 (minor allele C), MTHFR rs1801133, NPPA rs5063, nitric oxide synthase 3 rs1799983 (minor allele T) and transforming growth factor, beta 1 rs1800469 (minor allele T) were 0.96 (0.92-1.00), 1.06 (1.02-1.10), 0.88 (0.80-0.96), 1.05 (1.01-1.09) and 1.05 (1.01-1.10), respectively. After adjustment for multiple testing, none of these associations remained significant. CONCLUSION: NPPA gene polymorphisms may have a role in BP progression and incident hypertension. Our data also provide moderate confirmatory evidence of association between MTHFR rs1801133 and the development of hypertension.
OBJECTIVE: Genetic risk factors for essential hypertension are largely unknown. The aim of the present study was to assess the association of 77 previously characterized gene variants in 52 candidate genes from various biological pathways with blood pressure (BP) progression and incident hypertension. METHODS: We analyzed data from 18 738 white women who participated in a prospective cohort study and were free of hypertension at baseline. BP progression at 48 months and incident hypertension during the entire follow-up according to the different genotypes were assessed by logistic regression and Cox proportional-hazards models, respectively. RESULTS: At 48 months of follow-up, 7889 of 16 635 women (47.4%) had BP progression. Only three of 70 polymorphisms with a minor allele frequency of at least 2% had a significant association with BP progression. The odds ratio [95% confidence interval (CI)] for 5,10-methylenetetrahydrofolate reductase (MTHFR) rs1801133 (minor allele T), natriuretic peptide precursor A (NPPA) rs5063 (minor allele A) and NPPArs5065 (minor allele C) were 1.05 (1.00-1.10), 0.84 (0.76-0.94) and 0.93 (0.88-1.00), respectively. After adjustment for multiple testing using the false discovery rate, only the NPPArs5063 association remained significant. During a median follow-up of 9.8 years, 5540 of 18 738 women developed incident hypertension. Only five of 70 polymorphisms were significantly associated with incident hypertension. The hazard ratio (95% CI) for interleukin 6 (IL-6) rs1800795 (minor allele C), MTHFRrs1801133, NPPArs5063, nitric oxide synthase 3 rs1799983 (minor allele T) and transforming growth factor, beta 1 rs1800469 (minor allele T) were 0.96 (0.92-1.00), 1.06 (1.02-1.10), 0.88 (0.80-0.96), 1.05 (1.01-1.09) and 1.05 (1.01-1.10), respectively. After adjustment for multiple testing, none of these associations remained significant. CONCLUSION:NPPA gene polymorphisms may have a role in BP progression and incident hypertension. Our data also provide moderate confirmatory evidence of association between MTHFRrs1801133 and the development of hypertension.
Authors: Lisa F Barcellos; Ann B Begovich; Rebecca L Reynolds; Stacy J Caillier; David Brassat; Silke Schmidt; Sarah E Grams; Karen Walker; Lori L Steiner; Bruce A C Cree; Althea Stillman; Robin R Lincoln; Margaret A Pericak-Vance; Jonathan L Haines; Henry A Erlich; Stephen L Hauser; Jorge R Oksenberg Journal: Ann Neurol Date: 2004-06 Impact factor: 10.422
Authors: Thomas J Wang; Philimon Gona; Martin G Larson; Daniel Levy; Emelia J Benjamin; Geoffrey H Tofler; Paul F Jacques; James B Meigs; Nader Rifai; Jacob Selhub; Sander J Robins; Christopher Newton-Cheh; Ramachandran S Vasan Journal: Hypertension Date: 2007-01-22 Impact factor: 10.190
Authors: Leo A J Kluijtmans; Ian S Young; Colin A Boreham; Liam Murray; Dorothy McMaster; Helene McNulty; J J Strain; Joseph McPartlin; John M Scott; Alexander S Whitehead Journal: Blood Date: 2003-04-01 Impact factor: 22.113
Authors: Howard D Sesso; Julie E Buring; Nader Rifai; Gavin J Blake; J Michael Gaziano; Paul M Ridker Journal: JAMA Date: 2003-12-10 Impact factor: 56.272
Authors: Manjinder S Sandhu; Dawn M Waterworth; Sally L Debenham; Eleanor Wheeler; Konstantinos Papadakis; Jing Hua Zhao; Kijoung Song; Xin Yuan; Toby Johnson; Sofie Ashford; Michael Inouye; Robert Luben; Matthew Sims; David Hadley; Wendy McArdle; Philip Barter; Y Antero Kesäniemi; Robert W Mahley; Ruth McPherson; Scott M Grundy; Sheila A Bingham; Kay-Tee Khaw; Ruth J F Loos; Gérard Waeber; Inês Barroso; David P Strachan; Panagiotis Deloukas; Peter Vollenweider; Nicholas J Wareham; Vincent Mooser Journal: Lancet Date: 2008-02-09 Impact factor: 79.321
Authors: Jennifer E Ho; Daniel Levy; Lynda Rose; Andrew D Johnson; Paul M Ridker; Daniel I Chasman Journal: J Hypertens Date: 2011-01 Impact factor: 4.844
Authors: Ana C Dordea; Sara Vandenwijngaert; Victor Garcia; Robert E T Tainsh; Daniel I Nathan; Kaitlin Allen; Michael J Raher; Laurel T Tainsh; Fan Zhang; Wolfgang S Lieb; Sarah Mikelman; Andrew Kirby; Christine Stevens; Robrecht Thoonen; Allyson G Hindle; Patrick Y Sips; John R Falck; Mark J Daly; Peter Brouckaert; Kenneth D Bloch; Donald B Bloch; Rajeev Malhotra; Michal L Schwartzman; Emmanuel S Buys Journal: Am J Physiol Heart Circ Physiol Date: 2016-05-03 Impact factor: 4.733